The tweet was deleted by the author.
But we saved everything 🙂.
Upstream Bio, Inc. presented two new posters from the Phase 2 VIBRANT trial of verekitug for chronic rhinosinusitis with nasal polyps (CRSwNP) at ATS2026.
The data, which included findings on patients with comorbid asthma, was shared during the conference on Monday, offering new insights into therapeutic response for this challenging patient population. Posters P1397 and P1398 provided detailed results on the investigational antibody therapy in an area of high unmet need.
View post on X Loading...